Driven by
high growth witnessed by chronic therapies — anti-diabetics, cardiovascular,
vitamin and neutraceuticals, dermatological and to some extent anti-malaria
drugs — the domestic drug market continued to grow at a healthy 15.6% in July.
For the 12-month period ended July, the Indian drug market grew at a robust 17%
to touch R66,357 crore, according to pharma market research firm Aiocd Awacs.
“From a therapy
perspective, chronic therapies have done continued to do well for the month of
July, with anti-diabetic (29.7%), cardiac (21.5%). The vitamins and nutrients
market, neuro drugs and derma segment have clocked over 18% for the month,
while the anti-malaria market for the month registered a fast growth of 30%,”
said Hari Natarajan, head, pharmaTrac, Aiocd Awacs. He said companies with a
strong chronic drug portfolio have expectedly experienced high growth for the
month of June. In contrast, anti-infectives have grown by 8% in the month. Sun Pharma, one such company with a heavy tilt towards chronic therapies vis-à-vis acute therapies — prone to seasonal fluctuations — has grown 27% in July.
